Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein

Cell Reports

Volumn 10, Issue 4, 2015, Pages 600-615

  Strating, Jeroen R P M ^a,b   van der Linden, Lonneke ^b,c   Albulescu, Lucian ^a,b   Bigay, Joëlle ^d   Arita, Minetaro ^e   Delang, Leen ^c   Leyssen, Pieter ^c   van der Schaar, Hilde M ^a,b   Lanke, Kjerstin H W ^b   Thibaut, Hendrik Jan ^a   Ulferts, Rachel ^a,b   Drin, Guillaume ^d   Schlinck, Nina ^f   Wubbolts, Richard W ^g   Sever, Navdar ^h   Head, Sarah A ⁱ   Liu, Jun O ⁱ   Beachy, Philip A ^h   DeMatteis, Maria A ^j   Shair, Matthew D ^k   Olkkonen, Vesa M ^l   Neyts, Johan ^c   van Kuppeveld, Frank J M ^a,b   more..

^a UTRECHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^f NanoTemper Technologies GmbH   (Germany)

^g UTRECHT UNIVERSITY   (Netherlands)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^k HARVARD UNIVERSITY   (United States)

^l MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; ITRACONAZOLE; OXYSTEROL BINDING PROTEIN; OXYSTEROL BINDING PROTEIN RELATED PROTEIN 4; PHOSPHATIDYLINOSITOL 4 KINASE III BETA; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHATIDYLINOSITOL KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; STEROID RECEPTOR;

ARTICLE; CARDIOVIRUS; DRUG PROTEIN BINDING; ENTEROVIRUS; ENZYME ACTIVITY; GOLGI COMPLEX; HEPATITIS C VIRUS; INHIBITION KINETICS; LIPID EXCHANGE; LIPID TRANSPORT; MUTATIONAL ANALYSIS; PROTEIN LOCALIZATION; PROTEIN TARGETING; VIRUS GENOME; VIRUS INDUCTION; VIRUS REPLICATION; DRUG EFFECTS; HUMAN; METABOLISM; TUMOR CELL LINE;

COXSACKIEVIRUS; ENTEROVIRUS; HEPATITIS C VIRUS; HUMAN ENTEROVIRUS 71; POLIOVIRUS; RHINOVIRUS;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; ENTEROVIRUS; HUMANS; ITRACONAZOLE; RECEPTORS, STEROID; VIRUS REPLICATION;

EID: 84922769738     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.12.054     Document Type: Article

References (43)

1. Antonarakis E.S., Heath E.I., Smith D.C., Rathkopf D., Blackford A.L., Danila D.C., King S., Frost A., Ajiboye A.S., Zhao M., et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 2013, 18:163-173.
2. Arita M. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol. Immunol. 2014, 58:239-256.
3. Arita M., Wakita T., Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J.Gen. Virol. 2009, 90:1869-1879.
4. Arita M., Takebe Y., Wakita T., Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J.Gen. Virol. 2010, 91:2734-2744.
5. Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J.Virol. 2011, 85:2364-2372.
6. Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J.Virol. 2013, 87:4252-4260.
7. Balla A., Tuymetova G., Tsiomenko A., Várnai P., Balla T. A plasma membrane pool of phosphatidylinositol 4-phosphate is generated by phosphatidylinositol 4-kinase type-III alpha: studies with the PH domains of the oxysterol binding protein and FAPP1. Mol. Biol. Cell 2005, 16:1282-1295.
8. Belov G.A., Nair V., Hansen B.T., Hoyt F.H., Fischer E.R., Ehrenfeld E. Complex dynamic development of poliovirus membranous replication complexes. J.Virol. 2012, 86:302-312.
9. Beretta L., Svitkin Y.V., Sonenberg N. Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection. J.Virol. 1996, 70:8993-8996.
10. Burgett A.W., Poulsen T.B., Wangkanont K., Anderson D.R., Kikuchi C., Shimada K., Okubo S., Fortner K.C., Mimaki Y., Kuroda M., et al. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat. Chem. Biol. 2011, 7:639-647.
11. Charman M., Colbourne T.R., Pietrangelo A., Kreplak L., Ridgway N.D. Oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is essential for cell proliferation and survival. J.Biol. Chem. 2014, 289:15705-15717.
12. Chen J.K., Taipale J., Young K.E., Maiti T., Beachy P.A. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 2002, 99:14071-14076.
13. Cheng F., Liu C., Jiang J., Lu W., Li W., Liu G., Zhou W., Huang J., Tang Y. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 2012, 8:e1002503.
14. Doedens J.R., Giddings T.H., Kirkegaard K. Inhibition of endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: genetic and ultrastructural analysis. J.Virol. 1997, 71:9054-9064.
15. Hsu N.-Y., Ilnytska O., Belov G., Santiana M., Chen Y.-H., Takvorian P.M., Pau C., van der Schaar H., Kaushik-Basu N., Balla T., et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 2010, 141:799-811.
16. Ilnytska O., Santiana M., Hsu N.Y., Du W.L., Chen Y.H., Viktorova E.G., Belov G., Brinker A., Storch J., Moore C., et al. Enteroviruses harness the cellular endocytic machinery to remodel the host cell cholesterol landscape for effective viral replication. Cell Host Microbe 2013, 14:281-293.
17. Kim J., Tang J.Y., Gong R., Kim J., Lee J.J., Clemons K.V., Chong C.R., Chang K.S., Fereshteh M., Gardner D., et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010, 17:388-399.
18. Kim D.J., Kim J., Spaunhurst K., Montoya J., Khodosh R., Chandra K., Fu T., Gilliam A., Molgo M., Beachy P.A., Tang J.Y. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J.Clin. Oncol. 2014, 32:745-751.
19. Lestner J., Hope W.W. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin. Drug Metab. Toxicol. 2013, 9:911-926.
20. Limpens R.W.A.L., Van der Schaar H.M., Kumar D., Koster A.J., Snijder E.J., Van Kuppeveld F.J.M., Bárcena M. The transformation of enterovirus replication structures: a three-dimensional study of single- and double-membrane compartments. MBio. 2011, 2. e00166-11.
21. MacLeod A.M., Mitchell D.R., Palmer N.J., Van de Poël H., Conrath K., Andrews M., Leyssen P., Neyts J. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med. Chem. Lett. 2013, 4:585-589.
22. Mesmin B., Bigay J., Moser von Filseck J., Lacas-Gervais S., Drin G., Antonny B. A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi tether OSBP. Cell 2013, 155:830-843.
23. Nacev B.A., Grassi P., Dell A., Haslam S.M., Liu J.O. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J.Biol. Chem. 2011, 286:44045-44056.
24. Peretti D., Dahan N., Shimoni E., Hirschberg K., Lev S. Coordinated lipid transfer between the endoplasmic reticulum and the Golgi complex requires the VAP proteins and is essential for Golgi-mediated transport. Mol. Biol. Cell 2008, 19:3871-3884.
25. Perry R.J., Ridgway N.D. Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. Mol. Biol. Cell 2006, 17:2604-2616.
26. Raychaudhuri S., Prinz W.A. The diverse functions of oxysterol-binding proteins. Annu. Rev. Cell Dev. Biol. 2010, 26:157-177.
27. Rothwell C., Lebreton A., Young Ng C., Lim J.Y., Liu W., Vasudevan S., Labow M., Gu F., Gaither L.A. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009, 389:8-19.
28. Roulin P.S., Lötzerich M., Torta F., Tanner L.B., van Kuppeveld F.J., Wenk M.R., Greber U.F. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface. Cell Host Microbe 2014, 16:677-690.
29. Rudin C.M., Brahmer J.R., Juergens R.A., Hann C.L., Ettinger D.S., Sebree R., Smith R., Aftab B.T., Huang P., Liu J.O. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J.Thorac. Oncol. 2013, 8:619-623.
30. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000, 406:1005-1009.
31. van der Schaar H.M., van der Linden L., Lanke K.H., Strating J.R., Pürstinger G., de Vries E., de Haan C.A., Neyts J., van Kuppeveld F.J. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res. 2012, 22:1576-1592.
32. van der Schaar H.M., Leyssen P., Thibaut H.J., de Palma A., van der Linden L., Lanke K.H., Lacroix C., Verbeken E., Conrath K., Macleod A.M., et al. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ. Antimicrob. Agents Chemother. 2013, 57:4971-4981.
33. van Kuppeveld F.J., Galama J.M., Zoll J., Melchers W.J. Genetic analysis of a hydrophobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required for a cis-acting function in viral RNA synthesis. J.Virol. 1995, 69:7782-7790.
34. Walsky R.L., Bauman J.N., Bourcier K., Giddens G., Lapham K., Negahban A., Ryder T.F., Obach R.S., Hyland R., Goosen T.C. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab. Dispos. 2012, 40:1051-1065.
35. Wang C., JeBailey L., Ridgway N.D. Oxysterol-binding-protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments. Biochem. J. 2002, 361:461-472.
36. Wang E.J., Lew K., Casciano C.N., Clement R.P., Johnson W.W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 2002, 46:160-165.
37. Wang H., Perry J.W., Lauring A.S., Neddermann P., De Francesco R., Tai A.W. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. Gastroenterology 2014, 146:1373-1385, e1-e11.
38. Warrilow A.G., Parker J.E., Kelly D.E., Kelly S.L. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob. Agents Chemother. 2013, 57:1352-1360.
39. Weber-Boyvat M., Zhong W., Yan D., Olkkonen V.M. Oxysterol-binding proteins: functions in cell regulation beyond lipid metabolism. Biochem. Pharmacol. 2013, 86:89-95.
40. Wong J., Zhang J., Si X., Gao G., Mao I., McManus B.M., Luo H. Autophagosome supports coxsackievirus B3 replication in host cells. J.Virol. 2008, 82:9143-9153.
41. Wyles J.P., Perry R.J., Ridgway N.D. Characterization of the sterol-binding domain of oxysterol-binding protein (OSBP)-related protein 4 reveals a novel role in vimentin organization. Exp. Cell Res. 2007, 313:1426-1437.
42. Xu J., Dang Y., Ren Y.R., Liu J.O. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc. Natl. Acad. Sci. USA 2010, 107:4764-4769.
43. Zhang S., Pillai V.C., Mada S.R., Strom S., Venkataramanan R. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 2012, 42:409-416.